EpiCast Report: Hepatocellular Carcinoma - Epidemiology Forecast to 2024

Description:
Hepatocellular carcinoma (HCC) is a common type of primary liver cancer that arises from the hepatocytes in the liver. HCC is classified by various staging systems such as the Barcelona Clinic Liver Cancer (BCLC) stage and Child Pugh stages. The major risk factors for HCC are hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, and alcohol abuse. HCC is more common in men than women, averaging between two to four times as many cases in men as in women. This could be due to men being more likely to be infected with HBV and HCV, to consume more alcohol, to smoke cigarettes, or to have increased iron stores.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of HCC will increase from 103,308 cases in 2014 to 123,658 cases in 2024 at an Annual Growth Rate (AGR) of 1.97%. Japan had the highest number of diagnosed incident cases of HCC among the 7MM throughout the forecast period. In the 7MM in 2014 there were 38,359 diagnosed incident cases of BCLC stage A, 26,558 cases of BCLC stage B, 26,527 cases of BCLC stage C, and 11,865 cases of BCLC stage D. GlobalData epidemiologists estimated that the 7MM in 2014 had 150,488 five-year diagnosed prevalent cases of HCC, 10,835 diagnosed incident cases of HCC with HBV, and 62,140 diagnosed incident cases of HCC with HCV.

The overall increase in the incidence of HCC in the 7MM was mostly driven by population changes, as GlobalData epidemiologists observed very little historical changes in the incidence of HCC. During the forecast period, changes in alcohol use/abuse among men and women may impact the incidence of HCC in the US and UK. Furthermore, the high prevalence of HCV in Italy and Japan will continue to contribute to HCC incidence.

Our epidemiological forecast for the diagnosed incident and the five-year diagnosed prevalent cases of HCC in the 7MM is supported by age- and sex-specific data for the incidence. The one- to five-year relative survival data, which were used for the five-year diagnosed prevalent cases forecast, are supported by country-specific, population-based studies that are representative of the national population in the respective markets.

Scope
- The Hepatocellular Carcinoma (HCC) EpiCast Report provides an overview of the risk factors and global trends of HCC in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of HCC in these markets. The diagnosed incident cases of HCC are segmented by age (30–39 years, 40–49 years, 50–59 years, 60–69 years, and 70–79 years, ≥80 years), sex, BCLC stage at diagnosis, and comorbidity with HBV or HCV.
- The HCC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The HCC EpiCast series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global HCC market.
- Quantify patient populations in the global HCC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HCC therapeutics in each of the markets covered.
- Identify the percentage of HCC incident cases by stage at diagnosis and comorbidity with HBV or HCV.

Contents:
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global Trends
3.3.1 Incidence
3.3.2 Relative Survival
3.3.3 Stage at Diagnosis
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.5 Epidemiological Forecast of HCC (2014-2024)
3.5.1 Diagnosed Incident Cases of HCC
3.5.2 Age-Specific Diagnosed Incident Cases of HCC
3.5.3 Sex-Specific Diagnosed Incident of HCC
3.5.4 Age-Standardized Diagnosed Incidence of HCC
3.5.5 Diagnosed Incident Cases of HCC by BCLC Stages
3.5.6 Diagnosed Incident Cases of HCC with HBV and HCV Comorbidities
3.5.7 Five-Year Diagnosed Prevalent Cases of HCC
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 Physicians and Specialists Included in this Study
4.3 Primary Research - Prescriber Survey

4.4 About the Authors

4.4.1 Epidemiologists

4.4.2 Reviewers

4.4.3 Global Director of Therapy Analysis and Epidemiology

4.4.4 Global Head of Healthcare

4.5 About Us

4.6 About EpiCast

4.7 Disclaimer

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for HCC

Table 2: 7MM, Most Recent One-Year and Five-Year Relative Liver Cancer Survival in Men and Women

Table 3: US and Germany, Relative Survival Temporal Trend

Table 4: 7MM, BCLC and Child Pugh Stage at Diagnosis, Men and Women (%)

Table 5: 7MM, Sources Used for Diagnosed Incidence of HCC

Table 6: 7MM, Sources of Epidemiological Data Used for Diagnosed Incident Cases Segmented by BCLC Clinical Stages

Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Five-Year Diagnosed Prevalent Cases of HCC

Table 8: 7MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Incident Cases of HCC with HBV and HCV comorbidities.

Table 9: 7MM, Diagnosed Incident Cases of HCC, Both Sexes, Ages =30 years, N, 2014-2024

Table 10: 7MM, Age-Specific Diagnosed Incident Cases of HCC, Both Sexes, N, 2014

Table 11: 7MM, Sex-Specific Diagnosed Incident Cases of HCC, Ages =30 Years, N (Row %), 2014

Table 12: 7MM, Diagnosed Incident Cases of HCC by BCLC Stage, Ages =30 Years, N (Row %), 2014

Table 13: 7MM, Diagnosed Incident Cases of HCC with HBV and HCV, Ages =30 years, Both Sexes, N, 2014 (Row %)

Table 14: 7MM, Five-Year Diagnosed Prevalent Cases of HCC, Ages =30 Years, Both Sexes, N, 2014-2024

Table 15: High-Prescribing Physicians (non-KOL) Surveyed, By Country

1.2 List of Figures

Figure 1: 7MM, Diagnosed Incidence Rate of HCC (Cases per 100,000 Population), Ages =30 years, Both Sexes, 2004-2013

Figure 2: 7MM, Diagnosed Incident Cases of HCC, Ages =30 Years, Both Sexes, N, 2014-2024

Figure 3: 7MM, Age-Specific Diagnosed Incident Cases of HCC, Both Sexes, N, 2014
Figure 4: 7MM, Diagnosed Incident Cases of HCC, Ages =30 Years, N, 2014
Figure 5: 7MM, Age-Standardized Diagnosed Incidence Cases of HCC, Ages =30 Years, N, 2014
Figure 6: 7MM, Diagnosed Incident Cases of HCC by BCLC Stage, Ages =30 Years, Both Sexes N, 2014
Figure 7: 7MM, Diagnosed Incident Cases of HCC with HCV, Ages =30 Years, N, 2014
Figure 8: 7MM, Five-Year Diagnosed Prevalent Cases of HCC, Ages =30 Years, Both Sexes, N, 2014-2024

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3499678/](http://www.researchandmarkets.com/reports/3499678/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: EpiCast Report: Hepatocellular Carcinoma - Epidemiology Forecast to 2024
Web Address: http://www.researchandmarkets.com/reports/3499678/
Office Code: SCD2STCW

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 3995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 7990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 11985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof

First Name: ____________________________________________
Email Address: * _______________________________________
Job Title: _____________________________________________
Organisation: __________________________________________
Address: ______________________________________________
City: __________________________________________________
Postal / Zip Code: ______________________________________
Country: _______________________________________________
Phone Number: _________________________________________
Fax Number: __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
   27-35 Main Street,
   Blackrock,
   Co. Dublin,
   Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World